Powered by

Home Trending News

Shark Namita Thapar's Emcure Pharma Gets SEBI Approval For $3 Bn IPO

Emcure Pharma, led by Shark Tank India's Namita Thapar, has received SEBI approval for an IPO, expected within two months. The IPO includes ₹800 crore in new equity and an offer for sale of 1.36 crore shares.

By Rashaad Ather
New Update
Namita Thapar - Shark Tank India Judge

Namita Thapar - Executive Director At Emcure Pharma

Listen to this article
0.75x 1x 1.5x
00:00 / 00:00

Shark Tank India Judge Namita Thapar's Emcure Pharma has gotten the green light from SEBI for their IPO, and it looks like the company will be launching the issue within the next two months. 

Last year Emcure reportedly hired investment banks JP Morgan, Jefferies and Kotak for the IPO, and targeted a valuation of about $3 billion.

Emcure’s IPO will now include a fresh equity sale worth ₹800 crore and an offer for sale (OFS) of 1.36 crore equity shares by promoters and existing shareholders. 

In the OFS, the sellers will include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of the US-based private equity giant Bain Capital. 

Reason Behind Emcure's IPO:

According to media sources, the funds raised from the IPO will be used by the company to pay off debt and for general corporate purposes. 

Emcure Pharmaceuticals, based in Pune, backed by Bain Capital is surely making groundbreaking moves. 

Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the book-running lead managers for Emcure’s issue.